Quantum BioPharma is a pre-revenue, R&D-stage Canadian biopharmaceutical company focused on developing treatments for neurological and metabolic disorders. Its core asset is Lucid-MS (Lucid-21-302), a patented small-molecule drug candidate for progressive multiple sclerosis. Unlike existing approved MS therapies, which are immunomodulatory, Quantum argues that Lucid-MS works by inhibiting PAD2 and PAD4 enzymes that drive demyelination — the nerve fiber damage underlying MS — potentially preventing and reversing the disease process rather than just slowing immune attacks. Lucid-MS has completed Phase 1 safety trials in healthy humans with favorable results, and the company is working toward an FDA IND submission to begin a Phase 2 efficacy trial. Quantum also has a secondary drug program, FSD-PEA (FSD201), targeting mast cell activation syndrome, with a Phase 2 trial now underway in Australia. On the consumer side, Quantum developed a proprietary formulation that accelerates alcohol metabolism, which it has licensed to Unbuzzd Wellness — a company in which Quantum holds roughly a 20% equity stake — in exchange for a 7% gross royalty on cumulative sales up to US$250M. Quantum retains rights to a healthcare version of this formulation for hospital use. Beyond its drug programs, Quantum holds a cryptocurrency portfolio across Bitcoin, Ethereum, Solana, and other assets, valued at roughly US$5M, as a financial diversification strategy. The company funds operations entirely through equity and debt capital markets, with no commercial revenue.